Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588806 · ClinicalTrials.gov registry record · Phase 4
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills
A Phase 4 study, sponsored by Ajay Wasan, MD, Msc.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03588806: Clinical Trial Phase 4 study, sponsored by Ajay Wasan, MD, Msc.
NCT03588806 is a Phase 4 study that was terminated before completion, run by Ajay Wasan, MD, Msc. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03588806, a Phase 4 study, was terminated before completion, sponsored by Ajay Wasan, MD, Msc.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will examine how the use of Xtampza ER, an opioid analgesic packaged in openable microsphere-containing capsules, affects swallowing satisfaction, pain, and physical and mental health outcomes in chronic pain patients.
Primary Outcome
Percent change in pain intensity (in the last 24 hours) from baseline to the end of the study averaged over the last 7 days before clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable." As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score.
Interventions
- DRUG Xtampza ER (oxycodone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 4 |
Why NCT03588806 stopped before completion
NCT03588806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Xtampza ER (oxycodone) is the first listed.
NCT03588806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03588806 about?
NCT03588806 is a clinical study titled "Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills". This study will examine how the use of Xtampza ER, an opioid analgesic packaged in openable microsphere-containing capsules, affects swallowing satisfaction, pain, and physical and mental health outcomes in chronic pain patients.
What is the current status of trial NCT03588806?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-05-01. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT03588806?
The interventions under investigation include: Xtampza ER (oxycodone) (DRUG).
Who is sponsoring clinical trial NCT03588806?
This trial is sponsored by Ajay Wasan, MD, Msc, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03588806's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI